Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Portola's Xarelto/Eliquis Antidote To Be Refiled Next Year

ApproveOnKeyboard_1200x675 — • Source: Shutterstock

Related Content

Barner Goes Out On A High As Boehringer Ingelheim Returns To Growth

Apr 19 2016

Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff

Aug 19 2016

Related Companies

Portola Pharmaceuticals, Inc.

Johnson & Johnson

Bayer AG

Bristol Myers Squibb Company

Pfizer Inc.

Daiichi Sankyo Co., Ltd.

Sanofi

Additional Topics

Commercial Cardiovascular BioPharmaceutical

More from Cardiovascular

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window